Canaccord Genuity Group Reaffirms “Buy” Rating for Intellia Therapeutics (NASDAQ:NTLA)
Canaccord Genuity Group reissued their buy rating on shares of Intellia Therapeutics (NASDAQ:NTLA – Free Report) in a report issued on Thursday morning, Benzinga reports. The brokerage currently has a $73.00 price target on the stock. A number of other equities analysts have also weighed in on NTLA. Wedbush reissued a neutral rating and issued […]
More Stories
Lennar Co. (LEN) to Issue Quarterly Dividend of $0.50 on October 24th
Lennar Co. (NYSE:LEN – Get Free Report) announced a quarterly dividend on Wednesday, September 25th, NASDAQ reports. Shareholders of record...
Industria de Diseño Textil, S.A. (OTCMKTS:IDEXY) Plans Dividend of $0.29
Industria de Diseño Textil, S.A. (OTCMKTS:IDEXY – Get Free Report) announced a dividend on Saturday, October 5th, NASDAQ reports. Investors...
Freehold Royalties Ltd. (TSE:FRU) Given Average Rating of “Moderate Buy” by Analysts
Freehold Royalties Ltd. (TSE:FRU – Get Free Report) has received a consensus rating of “Moderate Buy” from the eight research...
Apogee Enterprises (NASDAQ:APOG) Updates FY 2025 Earnings Guidance
Apogee Enterprises (NASDAQ:APOG – Get Free Report) issued an update on its FY 2025 earnings guidance on Friday morning. The...
NAOS Emerging Opportunities Company Limited (ASX:NCC) Plans Final Dividend of $0.02
NAOS Emerging Opportunities Company Limited (ASX:NCC – Get Free Report) declared a final dividend on Thursday, October 3rd, MarketIndexAU reports....
Manhattan Bridge Capital, Inc. (NASDAQ:LOAN) to Issue Quarterly Dividend of $0.12
Manhattan Bridge Capital, Inc. (NASDAQ:LOAN – Get Free Report) announced a quarterly dividend on Friday, July 26th, Zacks reports. Investors...